Application of urine exosome protein marker in preparation of kidney cancer detection product
By screening VCAM1, ANGPTL2, ITGAM, C1QB, and CD68 proteins in urinary exosomes as biomarkers for renal cell carcinoma, and combining them with targeted proteomics technology for quantitative detection, the problem of the lack of reliable biomarkers for early diagnosis of renal cell carcinoma has been solved, achieving highly sensitive non-invasive detection and clinical guidance.
Patent Information
- Application Number
- CN202411122897.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-08
AI Technical Summary
Current technologies lack reliable biomarkers for the early diagnosis of renal cell carcinoma, and existing biomarkers are not significant in predicting the efficacy of ICI treatment. Liquid biopsy methods also present challenges in multicenter studies.
Through non-target proteomics analysis, VCAM1, ANGPTL2, ITGAM, C1QB, and CD68 proteins were screened as biomarkers for renal cell carcinoma detection. Targeted proteomics technology was used for quantitative detection, and PRM technology was used to replace antibody-based methods, overcoming the problems of difficult antibody preparation and poor specificity.
It provides an economical and convenient non-invasive method for early screening of renal cell carcinoma, improves the sensitivity and accuracy of detection, guides clinicians in further testing, and has good clinical application effectiveness.
Smart Images

Figure CN118914568A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biological detection technology, and specifically relates to the application of urine exosome protein markers in the preparation of kidney cancer detection products. Background Art
[0002] Renal cell carcinoma (RCC) is a malignant tumor originating from the renal tubular epithelium, accounting for 80% to 90% of renal malignant tumors. The most common histopathological type of renal cancer is clear cell carcinoma, which accounts for about 60% to 85% of renal cancer. In clinical practice, early renal cancer often lacks clinical manifestations, and about 60% of patients have reached at least T3 stage when discovered, so early diagnosis of RCC is of great significance. If renal cancer is still in the early stage at the time of diagnosis, that is, clinically limited renal cancer, the prognosis is good after surgical treatment. Once diagnosed as distant metastatic renal cancer, the prognosis is poor. Early detection, early diagnosis, and early treatment of renal cancer are the key to improving patient survival rates.
[0003] Currently, there is no recognized tumor marker for early auxiliary diagnosis of renal cancer. Renal cancer progresses rapidly, and its surgical treatment is also very costly. Renal cancer cells are insensitive to both radiotherapy and chemotherapy, and the value of immunotherapy remains to be verified. While targeted drugs have achieved gratifying therapeutic effects, their side effects and drug resistance pose new challenges to the treatment of renal cancer. Therefore, finding reliable biomarkers for the early diagnosis and prognosis of renal cancer is an important clinical topic, and it also has broad prospects for clinical transformation.
[0004] With the advancement of medical technology and the discovery of new therapies, certain results have been achieved in the early diagnosis and treatment of RCC. Liquid biopsy can provide real-time feedback on the patient's condition by collecting body fluids such as blood, urine, sweat or saliva in a minimally invasive manner to study the contents of circulating tumor cells and circulating RNA, tumor-induced platelets, extracellular vesicles (EVs) and free RNA or microRNA (miRNA). Each of these can be used independently or in combination as a biomarker for cancer, and has great potential. As an innovative technology for in vitro diagnosis, liquid biopsy technology has the advantages of low invasiveness, continuous sampling, and the ability to detect cancer at an earlier stage.
[0005] With the development of technology, urine and urine exosome proteomic analysis has become one of the most concerned research areas for biomarker discovery. On the one hand, urine contains plasma proteins filtered by the kidneys and proteins secreted by the urinary system, which can understand changes in human health and disease status. On the other hand, compared with blood proteins, which change more steadily, urine proteins can reflect changes in the body due to diseases earlier and more sensitively. Compared with tissue samples and blood samples, urine samples have unique advantages: 1. Non-invasive sampling, easy to obtain large volume samples; 2. Dynamic analysis and monitoring; 3. Reflect the earlier stage of the disease; 4. Low complexity, easier to detect low-abundance proteins. Therefore, urine is also known as a "gold mine" for finding biomarkers. Mining this gold mine may greatly promote the development of precision medicine, and also illustrate the important value and significance of urine testing. For example, high expression of miR-21, miR-378, miR-144-3p in tissue and serum of patients with renal cancer, and miR-15a and miR-30c-5p in urine exosomes may become indicators for early diagnosis of renal cancer. There is little research on proteins. A group of proteins consisting of CD10, MMP9, EMMPRIN, CAIX, DPEP1, DKK4, Syntenin 1 and AQP1 can distinguish between patients with renal cancer and healthy people, which is of great significance for the diagnosis of renal cancer. Urine analysis has the characteristics of early detection and sensitive detection, especially without the need for tissue puncture pathological analysis of patients, thus eliminating the need for complex equipment or highly skilled personnel.
[0006] Many studies have shown that numerous biomarkers have been discovered in renal cancer, however, so far, only a few markers have entered the clinical stage. For example, TMB, TIL, and PD-L1 expression, despite their great contributions in the research field, these biomarkers have not been able to successfully predict the efficacy of ICI-based treatment. Liquid biopsy can overcome spatial and temporal genetic heterogeneity, capturing the entire tumor and sampling throughout the disease progression. For example, ctDNA and CTCs can be used as biomarkers for renal cancer prediction. However, such biomarkers are very challenging for lesions with significantly different biological backgrounds, requiring larger-scale cross-center studies, practical methodological research, and consensus on accuracy to promote the development and application of results. Therefore, the discovery of mature and reliable biomarkers and the establishment of detection methods with good sensitivity and repeatability are very important for the clinical detection of renal cancer. Summary of the invention
[0007] In view of the shortcomings of the prior art, the purpose of the present invention is to provide the application of urine exosome protein markers in the preparation of renal cancer detection products. The present invention uses non-targeted proteomics to perform differential protein analysis on urine exosomes of renal cancer patients and urine exosomes of healthy people, and discovers potential biomarkers. Through bioinformatics analysis, VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins were screened as biomarkers for renal cancer detection.
[0008] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0009] In a first aspect, the present invention provides the use of urine protein markers in the preparation of a renal cancer detection product, wherein the urine protein markers include VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins.
[0010] In the present invention, the amino acid sequences of the detection proteins are shown as VCAM1 (Q53FL7_HUMAN), ANGPTL2 (Q9UKU9_HUMAN), ITGAM (P11215_HUMAN), C1QB (P02746_HUMAN), and CD68 (P34810_HUMAN).
[0011] In the present invention, the sequences of the above proteins can be queried at the following website, UniProtKB / TrEMBL (https: / / www.uniprot.org).
[0012] At present, there is a lack of universally recognized detection standards in the field of tumor marker research, and more research teams engaged in tumor marker development lack clinical tumor diagnosis and treatment experience. Based on actual clinical problems, the present invention discovers tumor markers that can be jointly detected from mass spectrometry sequencing of clinical sample arrays. The present invention focuses on the detection of combined indicators, including the early discovery and verification of tumor markers, and the research and development of combined markers, which have good clinical application effectiveness, so that patients who can be used to guide clinical decision-making will have better clinical expectations than patients who have not undergone tumor marker testing.
[0013] In a second aspect, the present invention provides the use of a reagent for detecting the content of urinary exosome protein markers in the preparation of a product for diagnosing and / or monitoring renal cancer, wherein the urinary exosome protein markers include VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins.
[0014] In a third aspect, the present invention provides a method for detecting the content of urine exosome protein markers based on targeted proteomics, wherein the urine exosome protein markers include VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins; the method comprises:
[0015] (1) Extraction of urine exosome protein markers;
[0016] (2) Denaturing, reducing, alkylating and enzymatically digesting the protein, collecting peptide fragments and preparing samples to be tested;
[0017] (3) preparing standard solutions containing characteristic peptides at different concentrations, wherein the standard solutions also include isotope internal standard peptides, and performing mass spectrometry detection; the characteristic peptides for detecting VCAM1 protein include any one of SEQ ID NOs: 1-3; the characteristic peptides for detecting ANGPTL2 protein include any one of SEQ ID NOs: 4-6; the characteristic peptides for detecting ITGAM protein include any one of SEQ ID NOs: 7-9; the characteristic peptides for detecting C1QB protein include any one of SEQ ID NOs: 10-12; the characteristic peptides for detecting CD68 protein are SEQ ID NO: 13;
[0018] (4) A standard curve is drawn according to the concentration of the standard solution and the peak area ratio of the characteristic peptide or the isotope internal standard peptide, and the concentration of the characteristic peptide in the sample to be tested is obtained based on the standard curve, thereby achieving quantitative detection of the urine exosome protein marker in the sample to be tested.
[0019] SEQ ID NO: 1: GSYSLVEAQK;
[0020] SEQ ID NO:2: ELQVYISP;
[0021] SEQ ID NO: 3: LHIDEMDSVPTVR;
[0022] SEQ ID NO:4:LQALEDGHDTSSIYLVKPENTNR;
[0023] SEQ ID NO:5: AHYQK;
[0024] SEQ ID NO:6: HDPGGWTVIQR;
[0025] SEQ ID NO:7: AIMEFNPR;
[0026] SEQ ID NO:8:DHVFQVNNFEALK;
[0027] SEQ ID NO:9: EFVSTVMEQLK;
[0028] SEQ ID NO:10:FDHVITNMNNNYEPR;
[0029] SEQ ID NO: 11: LEQGENVFLQATDK;
[0030] SEQ ID NO:12: GNLCVNLMR;
[0031] SEQ ID NO: 13: LQAAQLPHTGVFGQSFSCPSDR.
[0032] The present invention develops a detection method suitable for detecting urine protein markers in urine. The PRM technology - mass spectrometry-based targeted verification proteomics technology is used to replace antibody-based Western Blot, ELISA and other technologies. The advantage of the present invention is that it overcomes the problems of difficult antibody preparation and poor specificity. The present invention uses this technical principle to quantitatively identify the protein abundance of urine exosome protein markers.
[0033] Preferably, in step (1), the extraction step comprises: collecting urine from the subject, performing a first centrifugation, collecting the supernatant for a second centrifugation, collecting the supernatant for filtering, and performing ultracentrifugation on the obtained filtrate to obtain urinary exosome protein markers.
[0034] Preferably, the centrifugal force of the first centrifugation is 2000-3000g, for example, it can be 2000g, 2200g, 2400g, 2600g, 2800g or 3000g, etc., and the time is 20-30min, for example, it can be 20min, 22min, 24min, 26min, 28min or 30min, etc.
[0035] Preferably, the centrifugal force of the second centrifugation is 10000-12000g, for example, 10000g, 11000g, 11500g or 12000g, etc., and the time is 30-50min, for example, 20min, 22min, 24min, 26min, 28min or 30min, etc.
[0036] Preferably, the pore size of the filter used for the filtration is 0.2-0.22 μm, for example, 0.2 μm, 0.21 μm or 0.22 μm.
[0037] Preferably, the centrifugal force used in the ultracentrifugation is 100000-120000 g, such as 100000 g, 110000 g or 120000 g, etc., and the time is 70-100 min, such as 70 min, 80 min, 90 min or 100 min, etc.
[0038] In a fourth aspect, the present invention provides a model for diagnosing and / or monitoring renal cancer, the model comprising:
[0039] A detection module, used to detect the content of urine exosome protein markers of a subject, wherein the urine exosome protein markers include VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins;
[0040] A data analysis module, used to calculate the ratio of the content of the urinary exosome protein marker of the subject to the content of the urinary exosome protein marker of the normal control;
[0041] The result output module is used to determine whether the subject suffers from kidney cancer based on the ratio.
[0042] Preferably, the judgment criteria are:
[0043] The subject is judged to have renal cancer if the ratio of the subject's VCAM1 protein content to the control is greater than or equal to 3.3, the ratio of the subject's ANGPTL2 protein content to the control is greater than or equal to 2.8, the ratio of the subject's ITGAM protein content to the control is greater than or equal to 2.2, the ratio of the subject's C1QB protein content to the control is greater than or equal to 2.2, and the ratio of the subject's CD68 protein content to the control is greater than or equal to 1.6.
[0044] Preferably, the detection module comprises:
[0045] Protein extraction unit, used to extract urine exosome protein markers;
[0046] The protein processing unit is used to denature, reduce, alkylate and digest proteins, collect peptides and prepare samples to be tested;
[0047] A mass spectrometry detection unit, used for performing mass spectrometry detection on standard solutions containing characteristic peptide segments of different concentrations and samples to be tested; the characteristic peptide segment for detecting VCAM1 protein includes any one of SEQ ID NOs: 1-3; the characteristic peptide segment for detecting ANGPTL2 protein includes any one of SEQ ID NOs: 4-6; the characteristic peptide segment for detecting ITGAM protein includes any one of SEQ ID NOs: 7-9; the characteristic peptide segment for detecting C1QB protein includes any one of SEQ ID NOs: 10-12; the characteristic peptide segment for detecting CD68 protein is SEQ ID NO: 13;
[0048] The protein quantification unit draws a standard curve according to the concentration of the standard solution and the peak area ratio of the characteristic peptide or isotope internal standard peptide, and obtains the concentration of the characteristic peptide in the sample to be tested based on the standard curve, thereby realizing the quantitative detection of the urine exosome protein marker in the sample to be tested.
[0049] In a fifth aspect, the present invention provides use of the model for diagnosing and / or monitoring renal cancer described in the fourth aspect in the preparation of a product for detecting renal cancer.
[0050] The numerical range described in the present invention not only includes the point values listed above, but also includes any point values between the above numerical ranges that are not listed. Due to space limitations and for the sake of simplicity, the present invention no longer exhaustively lists the specific point values included in the range.
[0051] Compared with the prior art, the present invention has the following beneficial effects:
[0052] (1) The present invention is based on liquid biopsy, which collects urine from patients with renal cancer non-invasively, which is economical and convenient. According to the detection of VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins in previous clinical samples, it is proved that the above proteins can be used as an indicator for early screening of renal cancer, which has guiding significance for clinicians to guide patients to the next step of testing.
[0053] (2) The present invention utilizes targeted proteomics to specifically detect VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins, thereby avoiding the problems of difficult antibody preparation and poor specificity, improving sensitivity and shortening detection time, and providing ideas for the development and application of new biomarkers. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1 This is a schematic diagram of the extraction, identification and mass spectrometry process of urine exosomes from patients with renal cancer.
[0055] Figure 2 This is the result graph of protein identification quantity of each sample.
[0056] Figure 3 This is the principal component analysis diagram of the renal cancer positive group and the negative control group.
[0057] Figure 4 It is a volcano plot of differentially expressed proteins. DETAILED DESCRIPTION
[0058] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0059] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0060] Example 1 Discovery of Urinary Exosomes VCAM1, ANGPTL2, ITGAM, C1QB and CD68 Proteins
[0061] (1) Extraction and identification of urine exosomes
[0062] About 100 mL of urine was collected from patients with renal cancer and healthy people. The urine was transferred to a centrifuge tube and balanced, centrifuged at 4°C, 2000g for 20 minutes, and the supernatant was transferred to a new centrifuge tube and the precipitate was discarded. The supernatant was further balanced and centrifuged at 4°C for 30 minutes at 10,000g, and the supernatant was recovered and the precipitate was discarded. The supernatant was filtered with a 0.22μm filter to filter out large vesicle particles and detached cell fragments. The supernatant was balanced and centrifuged at 4°C for 70 minutes at 100,000g. The supernatant was discarded, and the precipitate was resuspended with 40 mL 1× PBS. After resuspension, the urine was further balanced, centrifuged at 4°C for 100,000g, and the supernatant was discarded. The precipitate was resuspended with 70μL 1× PBS, which was the exosome. Fresh exosomes were identified using NTA and electron microscopy.
[0063] (2) Urine exosome protein sample preparation and mass spectrometry analysis
[0064] Urea was added to the extracted exosome suspension to denature the protein, and the protein concentration was determined using a BCA kit. 500 μg of cell protein lysate (60 mM Tris-HCl (pH 6.8), 2% SDS and 10% glycerol) was added to a 1.5 mL centrifuge tube and urea was added to a final concentration of 8 M. The volume was adjusted to 300 μL with lysate; 15 μL of 200 mM DTT was added for reduction at room temperature for 45 minutes, followed by 12 μL of 1 M IAA for alkylation at room temperature in the dark for 45 minutes, and then 60 μL of 200 mM DTT was added to terminate the alkylation, and the reaction was carried out at room temperature for 30 minutes. The sample after reduction and alkylation was transferred to a 0.5mL 10KD ultrafiltration tube, and 50mM ammonium bicarbonate was added to make up the solution volume to about 500μL. After centrifugal ultrafiltration at 14000g for 30 minutes at room temperature, the filtrate was discarded; 400μL of 50mM ammonium bicarbonate solution was added to the ultrafiltration tube three times, and ultrafiltration was performed at 14000g for 30 minutes respectively; 30μL of prepared pancreatic enzyme solution was added to the ultrafiltration tube, and the protein solution was mixed by pipetting with a pipette gun, and digested at 37°C for 14 hours; after digestion, the ultrafiltration tube was taken out and placed in a new collection centrifuge tube, 200μL of 50mM ammonium bicarbonate solution was added to the ultrafiltration tube, and ultrafiltration was performed at 14000g for 30 minutes at room temperature to collect peptides; 200μL of 50mM ammonium bicarbonate solution was added to the ultrafiltration tube twice respectively. 50mM ammonium bicarbonate solution was centrifuged and ultrafiltered for 30 minutes, and all the filtrate was finally recovered as the peptides obtained by protein digestion; the peptides were heated and evaporated in a SpeedVac vacuum concentrator, and the peptides were resuspended with 1 / 1000 formic acid, and the peptide concentration was determined using Nanodrop, and then the peptide concentration was diluted to 100ng / μL with 1 / 1000 formic acid, and the peptides were divided into mass spectrometry loading bottles with 600ng per tube and waited for mass spectrometry analysis.
[0065] (3) Proteomic analysis and differential protein screening
[0066] Protein identification and quantification of proteomics raw data: The Swiss-Prot FASTA file of human complete protein sequence was downloaded from UniProt. Six raw data were obtained for each sample, and a total of 408 raw data were obtained for 68 samples. The MaxQuant software (version: 1.6.10.43) was used to perform database retrieval protein identification and quantification on all data. The parameters were consistent with the MaxQuant search parameters of the quality control samples. Data filtering and preprocessing: The ProteinGroups file generated by MaxQuant was used for downstream analysis. First, contaminants, trypsin and anti-library proteins were filtered out, and proteins with at least one specific peptide were retained. IBAQ quantitative values were extracted, and proteins with valid quantitative values in at least 10 samples were retained. The normalize.quantiles function in the R / Bioconductor software package preprocessCore (version: 1.50.0) was used to correct the data for percentages. Missing values were replaced with the minimum valid value in the data. The data were log2 transformed, and the expression matrix obtained was used for downstream analysis. Differential analysis: The processed protein expression matrix was differentially analyzed using the R / Bioconductor software package limma
[34] (version: 3.44.3). The screening criteria for differentially expressed proteins in tumors relative to adjacent adjacent tissues were: adjusted P value less than 0.01 and fold change greater than 2.
[0067] The extraction, identification and mass spectrometry process of urine exosomes from patients with renal cancer is shown in Figure 1 ; The results of quality control and differential analysis of urine exosome proteomics in patients with renal cancer are shown in Figure 2 , Figure 3 and Figure 4 ; Among them, from Figure 2 It can be seen that the mass spectrometry collected urine exosomes from 19 renal cancer patients (R1-R19) and 16 (N1-N16) healthy people. During the mass spectrometry operation, a total of 35 quality control data were generated, and more than 4,000 proteins were stably identified; Figure 3 It can be seen that in order to evaluate the quality of mass spectrometry data, PCA analysis showed that the protein expression levels of renal cancer patient samples were significantly different from those of healthy human samples; Figure 4 It can be seen that the proteomic quantitative data of renal cancer patient samples were differentially analyzed compared with healthy human samples. The results showed that 110 proteins were found to be increased in the urine exosomes of renal cancer patients compared with healthy human samples, and 68 were decreased.
[0068] After analysis, we selected five differentially expressed proteins, VCAM1, ANGPTL2, ITGAM, C1QB, and CD68, as targets for joint detection. We found that the above proteins were not only highly expressed in renal cancer tissues, but also detected in urine and urine exosomes. Compared with healthy people, the above protein levels were significantly increased, making them the preferred choice as urine detection markers.
[0069] Example 2 Experimental design and operation of PRM targeted proteomics
[0070] (1) Peptide selection
[0071] The target proteins VCAM1, ANGPTL2, ITGAM, C1QB and CD68 were imported into Skyline software for the screening of target peptides. At the same time, suitable peptides were screened out based on LC-MS / MS analysis.
[0072] (2) Development of PRM methods
[0073] The detection mode was positive ion, the primary mass spectrometer scan range was set to 300-1800 m / s, the resolution was set to 60000 FWHM, the AGC was set to 3e6, and the maximum IT was set to 200 ms. After each primary MS scan, 20 PRM scans (MS2 scans) were collected according to the inclusion list, the observation window was set to 1.6 Th, the mass spectrometer scan resolution was set to 30000 FWHM, the AGC was set to 3e6, the maximum IT was set to 120 ms, and the MS2 collision mode was HCD, and the fragmentation energy of the HCD collision cell was set to 27.
[0074] (3) Sample preparation and mass spectrometry analysis
[0075] The high-abundance samples were extracted for protein and hydrolyzed by FASP, and the peptides were desalted by C18 Cartridge. The peptides were freeze-dried and then re-dissolved in 40 μL 0.1% formic acid solution for peptide quantification. The samples were subjected to mass spectrometry detection in the same manner as in Example 1.
[0076] (4) Obtaining and interpreting results
[0077] According to the results of targeted mass spectrometry, 1-5 peptides with reliable identification information and good chromatographic separation behavior in each target protein were finally determined for PRM quantitative analysis. According to the quantitative information of each candidate peptide of the target protein, the peptide ratio was averaged and calculated to obtain the quantitative information of the target protein. The data was processed by mass spectrometry quantitative analysis using Skyline software.
[0078] Among them, the characteristic peptide segment for detecting VCAM1 protein includes any one of SEQ ID NOs: 1-3; the characteristic peptide segment for detecting ANGPTL2 protein includes any one of SEQ ID NOs: 4-6; the characteristic peptide segment for detecting ITGAM protein includes any one of SEQ ID NOs: 7-9; the characteristic peptide segment for detecting C1QB protein includes any one of SEQ ID NOs: 10-12; the characteristic peptide segment for detecting CD68 protein is SEQ ID NO: 13.
[0079] The sequence looks like this:
[0080] SEQ ID NO: 1: GSYSLVEAQK;
[0081] SEQ ID NO:2: ELQVYISP;
[0082] SEQ ID NO: 3: LHIDEMDSVPTVR;
[0083] SEQ ID NO:4:LQALEDGHDTSSIYLVKPENTNR;
[0084] SEQ ID NO:5: AHYQK;
[0085] SEQ ID NO:6: HDPGGWTVIQR;
[0086] SEQ ID NO:7: AIMEFNPR;
[0087] SEQ ID NO:8:DHVFQVNNFEALK;
[0088] SEQ ID NO:9: EFVSTVMEQLK;
[0089] SEQ ID NO:10:FDHVITNMNNNYEPR;
[0090] SEQ ID NO: 11: LEQGENVFLQATDK;
[0091] SEQ ID NO:12: GNLCVNLMR;
[0092] SEQ ID NO: 13: LQAAQLPHTGVFGQSFSCPSDR.
[0093] Example 3 A method for detecting the content of VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins in urine based on targeted proteomics
[0094] This embodiment provides a method for detecting the content of VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins in urine based on targeted proteomics, the method comprising the following steps:
[0095] (1) Extraction of urine exosome proteins
[0096] Collect about 100 mL of urine from patients with renal cancer, transfer the urine to a centrifuge tube, balance it, centrifuge it at 4°C, 2000g for 20 minutes, transfer the supernatant to a new centrifuge tube, and discard the precipitate. After the supernatant is balanced again, centrifuge it at 10,000g for 30 minutes at 4°C, recover the supernatant, and discard the precipitate. Filter the supernatant with a 0.22μm filter to filter out large vesicle particles and detached cell fragments. Transfer the urine to an ultracentrifuge tube, centrifuge it at 100,000g for 70 minutes, wash the exosomes with PBS, centrifuge it again at 100,000g for 70 minutes, and then resuspend the exosomes with 50μL of frozen 1×PBS to obtain urine exosome proteins for subsequent mass spectrometry.
[0097] (2) Preparation of mass spectrometry samples
[0098] Protein digestion was performed based on the FASP protein sample preparation method. First, the protein sample was completely dissolved with SDS cell lysis buffer and the disulfide bonds were reduced; 8M urea was used to replace SDS and the reduced cysteine was alkylated by ultrafiltration; trypsin digestion was performed; the peptides were desalted using C18 Cartridge, and the peptides were lyophilized and re-dissolved in 40μL 0.1% formic acid solution, and the peptides were quantified and waited for mass spectrometry analysis. The method is the same as that of Example 2 for mass spectrometry sample preparation.
[0099] (3) Targeted mass spectrometry detection
[0100] The prepared peptide samples and characteristic peptides were resuspended with 0.1% FA. 1 μg of each peptide sample was taken into a clean 0.2 mL EP tube, and 1 pg of heavy-labeled peptide was added and mixed. Before loading, the sample was concentrated to a volume of about 10 μL in a low-temperature refrigerated centrifugal concentrator. The mixed peptides were subjected to PRM mass spectrometry analysis.
[0101] (4) Quantitative analysis of results
[0102] The mass spectrometry data file was used to construct a mass spectrometry library using Skyline software, and the preliminary mass spectrometry data was matched with the mass spectrometry library for PRM retrieval to obtain the PRM quantitative peak signal of the target peptide. The retrieval parameters were set as follows:
[0103] Digestive enzymes: Trypsin;
[0104] Peptide length: 7-25 amino acids;
[0105] Parent ions: 2-valent and 3-valent;
[0106] Daughter ions: 1-valent, 2-valent and 3-valent;
[0107] Product ion types: b, y and p;
[0108] Structural modification: oxidation and cystine carbamidomethylation;
[0109] Isotope modification: 13 C6 15 N4 marker;
[0110] Collection method: Targeted.
[0111] Select y and b daughter ion pairs (at least 3 pairs) with higher signal quality from the heavy-labeled and light-labeled peak signals of the corresponding peptides. High-quality light-labeled and heavy-labeled daughter ion peaks should appear and elute at the same time. The overall peak area between the light-labeled and heavy-labeled peptides is determined by these ion pairs. The relative ratio of the light-labeled and heavy-labeled peak areas reflects the expression levels of VCAM1, ANGPTL2, ITGAM, C1QB and CD68.
[0112] A standard curve is drawn according to the concentration of the standard solution and the peak area ratio of the characteristic peptide or isotope internal standard peptide, and the concentration of the characteristic peptide in the sample to be tested is obtained based on the standard curve, thereby achieving quantitative detection of VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins in the sample to be tested.
[0113] Example 4 A model for diagnosing and / or monitoring renal cancer
[0114] This embodiment provides a model for diagnosing and / or monitoring renal cancer, the model comprising:
[0115] A detection module for detecting the content of VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins in the urine of a subject, the detection module comprising:
[0116] Protein extraction unit, used for extraction of urine exosome proteins.
[0117] The protein processing unit is used to denature, reduce, alkylate and enzymatically digest urine exosome proteins, collect peptide fragments and prepare samples for testing.
[0118] The mass spectrometry detection unit is used to perform mass spectrometry detection on standard solutions containing characteristic peptide segments of different concentrations and samples to be tested.
[0119] The protein quantification unit draws a standard curve according to the concentration of the standard solution and the peak area ratio of the characteristic peptide or isotope internal standard peptide, and obtains the concentration of the characteristic peptide in the sample to be tested based on the standard curve, thereby realizing the quantitative detection of VCAM1, ANGPTL2, ITGAM, C1QB, and CD68 proteins in the sample to be tested.
[0120] A data analysis module, used to calculate the ratio of the content of VCAM1, ANGPTL2, ITGAM, C1QB, and CD68 proteins in the urine of the subject to the content of proteins in the urine of the normal control;
[0121] A result output module is used to judge whether the subject suffers from renal cancer according to the ratio; the judgment standard is: the ratio of the subject's VCAM1 protein content to the control is greater than or equal to 3.3, the ratio of the subject's ANGPTL2 protein content to the control is greater than or equal to 2.8, the ratio of the subject's ITGAM protein content to the control is greater than or equal to 2.2, the ratio of the subject's C1QB protein content to the control is greater than or equal to 2.2, and the ratio of the subject's CD68 protein content to the control is greater than or equal to 1.6, then the subject is judged to have renal cancer.
[0122] In summary, the present invention utilizes targeted proteomics technology to identify that VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins in the urine of patients with renal cancer can be used as biomarkers for the diagnosis of renal cancer. The detection results of VCAM1, ANGPTL2, ITGAM, C1QB and CD68 in urine of early clinical samples are used as an indicator for early screening of renal cancer. The biomarkers for the diagnosis of renal cancer of the present invention have guiding significance for clinicians in guiding patients in the next step of testing.
[0123] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.
Claims
1. The use of urine exosome protein markers in the preparation of renal cancer detection products, characterized in that: The urinary exosome protein markers include VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins.
2. Use of a reagent for detecting the content of exosome protein markers in urine in the preparation of a product for diagnosing and / or monitoring renal cancer, characterized in that: The urinary exosome protein markers include VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins.
3. A method for detecting the content of urine exosome protein markers based on targeted proteomics, characterized in that: The urine exosome protein markers include VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins; the method includes: (1) Extraction of urine exosome protein markers; (2) Denaturing, reducing, alkylating and enzymatically digesting the protein, collecting peptide fragments and preparing samples to be tested; (3) preparing standard solutions containing characteristic peptides at different concentrations, wherein the standard solutions also include isotope internal standard peptides, and performing mass spectrometry detection; the characteristic peptides for detecting VCAM1 protein include any one of SEQ ID NOs: 1-3; the characteristic peptides for detecting ANGPTL2 protein include any one of SEQ ID NOs: 4-6; the characteristic peptides for detecting ITGAM protein include any one of SEQ ID NOs: 7-9; the characteristic peptides for detecting C1QB protein include any one of SEQ ID NOs: 10-12; the characteristic peptides for detecting CD68 protein are SEQ ID NO: 13; (4) A standard curve is drawn according to the concentration of the standard solution and the peak area ratio of the characteristic peptide or the isotope internal standard peptide, and the concentration of the characteristic peptide in the sample to be tested is obtained based on the standard curve, thereby achieving quantitative detection of the urine exosome protein marker in the sample to be tested.
4. The method for detecting the content of urine exosome protein markers based on targeted proteomics according to claim 3, characterized in that: In step (1), the extraction step includes: collecting urine from the subject, performing a first centrifugation, collecting the supernatant for a second centrifugation, collecting the supernatant for filtering, and ultracentrifuging the obtained filtrate to obtain urinary exosome protein markers.
5. The method for detecting the content of urine exosome protein markers based on targeted proteomics according to claim 4, characterized in that: The centrifugal force of the first centrifugation is 2000-3000g, and the time is 20-30min; Preferably, the centrifugal force of the second centrifugation is 10000-12000 g, and the time is 30-50 min.
6. The method for detecting the content of urine exosome urine protein markers based on targeted proteomics according to claim 4 or 5, characterized in that: The pore size of the filter used in the filtration is 0.2-0.22 μm; Preferably, the centrifugal force of the ultracentrifugation is 100000-120000 g, and the time is 70-100 min.
7. A model for diagnosing and / or monitoring renal cancer, characterized in that: The model includes: A detection module, used to detect the content of urine exosome protein markers of a subject, wherein the urine exosome protein markers include VCAM1, ANGPTL2, ITGAM, C1QB and CD68 proteins; A data analysis module, used to calculate the ratio of the content of the urinary exosome protein marker of the subject to the content of the urinary exosome protein marker of the normal control; The result output module is used to determine whether the subject suffers from kidney cancer based on the ratio.
8. The model for diagnosing and / or monitoring renal cancer according to claim 7, characterized in that: In the result output module, the judgment criteria are: The subject is judged to have renal cancer if the ratio of the subject's VCAM1 protein content to the control is greater than or equal to 3.3, the ratio of the subject's ANGPTL2 protein content to the control is greater than or equal to 2.8, the ratio of the subject's ITGAM protein content to the control is greater than or equal to 2.2, the ratio of the subject's C1QB protein content to the control is greater than or equal to 2.2, and the ratio of the subject's CD68 protein content to the control is greater than or equal to 1.
6.
9. The model for diagnosing and / or monitoring renal cancer according to claim 7 or 8, characterized in that: The detection module comprises: Protein extraction unit, used to extract urine exosome protein markers; The protein processing unit is used to denature, reduce, alkylate and digest proteins, collect peptides and prepare samples to be tested; A mass spectrometry detection unit, used for performing mass spectrometry detection on standard solutions containing characteristic peptide segments of different concentrations and samples to be tested; the characteristic peptide segment for detecting VCAM1 protein includes any one of SEQ ID NOs: 1-3; the characteristic peptide segment for detecting ANGPTL2 protein includes any one of SEQ ID NOs: 4-6; the characteristic peptide segment for detecting ITGAM protein includes any one of SEQ ID NOs: 7-9; the characteristic peptide segment for detecting C1QB protein includes any one of SEQ ID NOs: 10-12; the characteristic peptide segment for detecting CD68 protein is SEQ ID NO: 13; The protein quantification unit draws a standard curve according to the concentration of the standard solution and the peak area ratio of the characteristic peptide or isotope internal standard peptide, and obtains the concentration of the characteristic peptide in the sample to be tested based on the standard curve, thereby realizing the quantitative detection of the urine exosome protein marker in the sample to be tested.
10. Use of the model for diagnosing and / or monitoring renal cancer according to any one of claims 7 to 9 in the preparation of a product for detecting renal cancer.
